A PYMNTS Company

Lundbeck, Merck and others accused of suppressing generic antidepressants

By  |  July 25, 2012

The European Commission issued a Statement of Objections to Danish pharmaceutical company Lundbeck and four generic groups alleging agreements were made to delay entry of generic versions of citalopram, a widely used antidepressant. Preliminary investigations indicate that Lundbeck conducted “value transfers” to generic competitors in the form of direct payments, guaranteed profits in distribution agreements, and the purchase of generic citalopram stock. In exchange, generic competitors may delay putting a generic citalopram on the market for up to two years to keep brand name prices high. Reuters reports Lundbeck denies the allegations and asserted full compliance with EU competition law.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    This investigation is the European Commission’s first case dealing with “pay for delay” agreements.

    Full content: The Information Daily Reuters

     

    Related content: Pharmaceutical Patents, Settlements, Reverse Payments, and Exclusion Review of Reverse-Payment Agreements: The Agencies, the Courts, Congress, and the European Commission

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.